Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo

All News

Obesity weight loss
New Research Findings, Diabetes, IDO,

GIP Receptor: Activation and Blockade Support Weight Loss

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that not only activate the GIP receptor (agonists) but…

weiterlesen
Diabetes, HI-MAG, IDO,

Re-Defining Obesity as a Disease

A new report of the Commission on Clinical Obesity, published in The Lancet Diabetes & Endocrinology and endorsed by over 75 medical organizations, has introduced a transformative framework that addresses the limitations of traditional BMI-based…

weiterlesen
The Lancet Diabetes & Endocrinology Commission on Clinical Obesity
Maus Türöffnertag 2024
Public Engagement, Diabetes, TDI, IDO, IDF, IDC,

Helmholtz Munich Opened Its Doors for "The Mouse"

Every year on October 3rd, the German broadcaster WDR organizes the event "Doors Open with The Mouse." This year, 770 companies and research institutions across Germany participated, welcoming children and parents under the theme "Working Together."…

weiterlesen
New Research Findings, Diabetes, IDO,

Scientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targets

Recent research underscores the critical role of adipocytes in storing fat, vital for organismal survival. Dysfunctional adipocytes can lead to metabolic disorders like type 2 diabetes and fatty liver disease, highlighting the importance of…

weiterlesen
Human adipocyte
Porträt Cristina Garcia Caceres
IDO,

Cristina García Cáceres successfully completed her ERC Project: Astrocyte-Neuronal Crosstalk in Obesity and Diabetes (AstroNeuroCrosstalk)

The studies conducted in this ERC project provided a more comprehensive understanding of how the hypothalamus controls energy balance and metabolic adaptations in response to hypercaloric diets, thereby contributing to our understanding of its…

weiterlesen
New Research Findings, Diabetes, IDR, IDO,

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target

Research targeting the insulin-inhibitory receptor, called inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. A novel study in mice with diet-induced obesity demonstrates that the knock-out of…

weiterlesen
IDR Beta cell Heterogeneity